SUNITINIB MALATE for Transitional cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 16 adverse event reports in the FDA FAERS database where SUNITINIB MALATE was used for Transitional cell carcinoma.
Most Reported Side Effects for SUNITINIB MALATE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 4,385 | 20.3% | 4,379 | 361 |
| Diarrhoea | 3,044 | 14.1% | 302 | 950 |
| Fatigue | 2,865 | 13.3% | 302 | 869 |
| Nausea | 2,032 | 9.4% | 235 | 729 |
| Neoplasm progression | 1,920 | 8.9% | 545 | 558 |
| Disease progression | 1,745 | 8.1% | 508 | 532 |
| Decreased appetite | 1,676 | 7.8% | 274 | 696 |
| Asthenia | 1,651 | 7.7% | 347 | 772 |
| Vomiting | 1,331 | 6.2% | 232 | 637 |
| Dysgeusia | 1,226 | 5.7% | 98 | 397 |
| Malaise | 1,202 | 5.6% | 170 | 526 |
| Hypertension | 1,126 | 5.2% | 93 | 406 |
| Weight decreased | 1,120 | 5.2% | 156 | 453 |
| Stomatitis | 985 | 4.6% | 90 | 306 |
| Pain in extremity | 977 | 4.5% | 88 | 267 |
Other Indications for SUNITINIB MALATE
Metastatic renal cell carcinoma (4,271)
Renal cell carcinoma (2,926)
Renal cancer (2,750)
Gastrointestinal stromal tumour (1,696)
Renal cancer metastatic (871)
Neoplasm malignant (646)
Product used for unknown indication (368)
Renal cancer stage iv (357)
Pancreatic neuroendocrine tumour (314)
Clear cell renal cell carcinoma (244)
Other Drugs Used for Transitional cell carcinoma
PEMBROLIZUMAB (1,951)
ENFORTUMAB VEDOTIN-EJFV (1,179)
GEMCITABINE (825)
ATEZOLIZUMAB (788)
CISPLATIN (672)
ENFORTUMAB VEDOTIN (649)
NIVOLUMAB (595)
AVELUMAB (554)
CARBOPLATIN (493)
GEMCITABINE\GEMCITABINE (255)